

## UPADACITINIB prolonged-release tablets (RINVOQ® ▼) for ulcerative colitis

The Cheshire and Merseyside Interim Area Prescribing Group recommends the prescribing of UPADACITINIB prolonged-release tablets (RINVOQ® ▼), by specialists only, for treating moderately to severely active ulcerative colitis in adults in accordance with NICE TA856.

### RED

[NICE technology appraisal \(TA\) 856](#) (04 January 2023) recommends upadacitinib, within its marketing authorisation, as an option for treating moderately to severely active ulcerative colitis in adults, only if:

- > conventional or biological treatment cannot be tolerated, or
- > the condition has not responded well enough or has stopped responding to these treatments, and
- > the company provides upadacitinib according to the commercial arrangement.<sup>1</sup>

If patients and clinicians consider upadacitinib to be one of a range of suitable treatment options, the least expensive treatment should be chosen (taking into account drug administration costs, dose needed and frequency, and product price per dose).<sup>1</sup>

Prescribing and monitoring should be retained by a specialist in the management of ulcerative colitis.

### Costing information

NICE does not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or £9,000 per 100,000 population). This is because upadacitinib is a further treatment option and the overall cost of treatment for this patient group will be similar.<sup>2</sup>

### References

1. National Institute for Health and Care Excellence. Technology Appraisal 856; [Upadacitinib for treating moderately to severely active ulcerative colitis](#), 4 January 2023. Accessed 20 January 2023.
2. National Institute for Health and Care Excellence. Resource Impact Statement [TA856]; [Upadacitinib for treating moderately to severely active ulcerative colitis](#), 4 January 2023. Accessed 20 January 2023.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.